Nationwide Fund Advisors Has $8.01 Million Holdings in GlaxoSmithKline plc (GSK)

Nationwide Fund Advisors decreased its holdings in shares of GlaxoSmithKline plc (NYSE:GSK) by 20.9% in the third quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 197,317 shares of the pharmaceutical company’s stock after selling 52,035 shares during the period. Nationwide Fund Advisors’ holdings in GlaxoSmithKline were worth $8,011,000 as of its most recent SEC filing.

A number of other institutional investors and hedge funds have also made changes to their positions in the business. 1st Global Advisors Inc. lifted its stake in GlaxoSmithKline by 0.4% during the second quarter. 1st Global Advisors Inc. now owns 5,271 shares of the pharmaceutical company’s stock worth $227,000 after purchasing an additional 19 shares during the period. King Luther Capital Management Corp lifted its stake in GlaxoSmithKline by 1.0% during the second quarter. King Luther Capital Management Corp now owns 5,432 shares of the pharmaceutical company’s stock worth $234,000 after purchasing an additional 55 shares during the period. Loring Wolcott & Coolidge Fiduciary Advisors LLP MA lifted its stake in GlaxoSmithKline by 1.9% during the second quarter. Loring Wolcott & Coolidge Fiduciary Advisors LLP MA now owns 3,374 shares of the pharmaceutical company’s stock worth $137,000 after purchasing an additional 64 shares during the period. Strategic Global Advisors LLC lifted its stake in GlaxoSmithKline by 0.6% during the second quarter. Strategic Global Advisors LLC now owns 12,179 shares of the pharmaceutical company’s stock worth $525,000 after purchasing an additional 75 shares during the period. Finally, PagnatoKarp Partners LLC lifted its stake in GlaxoSmithKline by 1.4% during the second quarter. PagnatoKarp Partners LLC now owns 5,812 shares of the pharmaceutical company’s stock worth $253,000 after purchasing an additional 80 shares during the period. Hedge funds and other institutional investors own 9.83% of the company’s stock.

Shares of GlaxoSmithKline plc (NYSE GSK) opened at $35.17 on Friday. The firm has a market cap of $86,495.02, a P/E ratio of 12.47, a PEG ratio of 1.95 and a beta of 0.98. The company has a debt-to-equity ratio of 2.96, a quick ratio of 0.44 and a current ratio of 0.64. GlaxoSmithKline plc has a fifty-two week low of $34.52 and a fifty-two week high of $44.53.

The company also recently disclosed a quarterly dividend, which will be paid on Thursday, January 11th. Stockholders of record on Friday, November 10th will be issued a dividend of $0.5037 per share. This is a positive change from GlaxoSmithKline’s previous quarterly dividend of $0.49. The ex-dividend date of this dividend is Thursday, November 9th. This represents a $2.01 annualized dividend and a dividend yield of 5.73%. GlaxoSmithKline’s dividend payout ratio (DPR) is presently 163.12%.

A number of brokerages have commented on GSK. Argus cut their price target on shares of GlaxoSmithKline to $40.00 and set a “buy” rating for the company in a research note on Thursday, November 30th. UBS raised shares of GlaxoSmithKline from a “neutral” rating to a “buy” rating and raised their price objective for the stock from $35.04 to $35.85 in a report on Monday, November 27th. Investec lowered shares of GlaxoSmithKline from a “buy” rating to a “hold” rating in a report on Monday, November 6th. TheStreet raised shares of GlaxoSmithKline from a “c+” rating to a “b” rating in a report on Wednesday, October 25th. Finally, Bank of America lowered shares of GlaxoSmithKline from a “buy” rating to a “neutral” rating in a report on Thursday, October 26th. Three analysts have rated the stock with a sell rating, ten have given a hold rating and six have assigned a buy rating to the company. The stock has an average rating of “Hold” and an average price target of $39.71.

In other news, major shareholder Plc Glaxosmithkline acquired 428,571 shares of the company’s stock in a transaction dated Monday, November 6th. The stock was bought at an average price of $14.00 per share, with a total value of $5,999,994.00. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Company insiders own 10.00% of the company’s stock.

ILLEGAL ACTIVITY NOTICE: This piece of content was first published by The Ledger Gazette and is owned by of The Ledger Gazette. If you are accessing this piece of content on another publication, it was illegally stolen and reposted in violation of U.S. & international copyright and trademark law. The correct version of this piece of content can be accessed at https://ledgergazette.com/2017/12/10/nationwide-fund-advisors-has-8-01-million-holdings-in-glaxosmithkline-plc-gsk.html.

GlaxoSmithKline Profile

GlaxoSmithKline plc is a global healthcare company. The Company operates through three segments: Pharmaceuticals, Vaccines and Consumer Healthcare. The Company focuses on its research across six areas: Respiratory diseases, human immunodeficiency virus (HIV)/infectious diseases, Vaccines, Immuno-inflammation, Oncology and Rare diseases.

Want to see what other hedge funds are holding GSK? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for GlaxoSmithKline plc (NYSE:GSK).

Institutional Ownership by Quarter for GlaxoSmithKline (NYSE:GSK)

Receive News & Ratings for GlaxoSmithKline plc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for GlaxoSmithKline plc and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply